Caristo has been supporting multiple pharmaceutical and biotech companies’ development efforts by leveraging our capabilities in assessing coronary inflammation, plaque, and radiotranscriptomic profiling.
Caristo can support both pre-clinical and clinical stage drug trials, including:
New Amsterdam, a leading pharma company, partners with Caristo in the REMRANDT trial. This pivotal trial evaluates the effects of Obicetrapib on coronary plaque and inflammation, and Caristo has been selected as the worldwide imaging core lab to measure and monitor these critical indicators.
Read Press Release
Abcentra LLC, a clinical-stage biopharmaceutical company partnered with Caristo as worldwide imaging core Lab for coronary inflammation and plaque measurement and monitoring, for the FORTIFY clinical trial. The Phase 2B FORTIFY trial, evaluates the effects of Orticumab in patients with coronary artery disease.
Read Press Release
Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment (LODOCO®-- colchicine, 0.5 mg tablets), announced that they will collaborate with Caristo to improve awareness and clinical education about the central role of inflammation in coronary artery disease.
Read Press ReleaseInterested in collaborating with us?
Get in touch with the Caristo Team here
